{"id":55229,"date":"2023-03-28T00:03:08","date_gmt":"2023-03-27T22:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/"},"modified":"2023-03-28T00:03:08","modified_gmt":"2023-03-27T22:03:08","slug":"cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/","title":{"rendered":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization.\n<\/p>\n

\n\u201cIt is a great privilege for Cytonus to be joined by Dr. Houston, who has contributed important advances in the field of mRNA therapeutics,\u201d said Richard Klemke, PhD., Cytonus\u2019 cofounder and Chief Scientific Officer.\n<\/p>\n

\nCytonus\u2019 Scientific Advisor Board is comprised of accomplished business leaders, distinguished research scientists, and key opinion leaders from prestigious academic institutions, immune-oncology centers, cell therapy centers and private industry.\n<\/p>\n

\n\u201cI am excited to join the Scientific Advisory Board of Cytonus Therapeutics and feel it’s critical to advance delivery systems other than LNPs to target diseases beyond the liver,\u201d said Dr. Houston. \u201cCargocytes are novel delivery vehicles which enable delivery of a variety of biological agents to a variety of tissues and organs, including tumors, the brain and fibrotic tissues.\u201d\n<\/p>\n

\nDr. Houston brings over 25 years of experience as a leader in the biotech and pharmaceutical industries to Cytonus. As Chief Scientific Officer of TriLink he led teams developing new mRNA capping technologies as well as optimizing processes for making mRNA therapeutics and vaccines.\n<\/p>\n

\n\u201cThe expertise and operational perspectives of Dr. Houston will help accelerate the realization of our shared vision for Cytonus as a new and differentiated mRNA based therapeutic company,\u201d said Remo Moomiaie-Qajar, MD., Cytonus\u2019 cofounder and CEO. \u201cThe field of mRNA therapeutics is currently anchored to Lipid Nano Particle usage as an approach; at Cytonus we are utilizing mRNA in a highly differentiated approach via our Cargocyte platform. Dr. Houston has been influential in the growth of the industry and TriLink and we are extremely excited to work with him to realize the next generation of mRNA therapeutics.\u201d\n<\/p>\n

\nPrior to TriLink, Dr. Houston was the Chief Scientific Officer at PhaseRx, where he developed mRNA-based therapeutics. He also served as Vice President of Chemistry and Formulations for Marina Biotech, where he led a team in the development of siRNA-based therapies and LNP-based delivery systems.\n<\/p>\n

\nDr. Houston has considerable experience in peptide-based therapeutics, as demonstrated in his role as Vice President of Preclinical Chemistry and CMC at Ascent Therapeutics. He also served as Senior Director of Chemistry and Formulations at Nastech Pharmaceutics. He received a Ph.D. in bio-organic chemistry and a B.Sc. with honors in chemistry from the University of Waterloo in Ontario, Canada.\n<\/p>\n

\nAbout Cytonus Therapeutics, Inc.<\/b>\n<\/p>\n

\nCytonus is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte\u2122 technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes\u2122 are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies.\n<\/p>\n

\nFor more information, visit www.cytonus.com<\/a> and follow Cytonus on LinkedIn and on Twitter at: @CytonusTx.\n<\/p>\n

\nStatements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products, and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.\n<\/p>\n

Contacts<\/b> <\/p>\n

\npress@cytonus.com<\/a><\/b>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization. \u201cIt is a great privilege for Cytonus to be joined by Dr. Houston, who has contributed important advances in the field of mRNA therapeutics,\u201d said … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55229","6":"format-standard","7":"category-industry"},"yoast_head":"\nCytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization. \u201cIt is a great privilege for Cytonus to be joined by Dr. Houston, who has contributed important advances in the field of mRNA therapeutics,\u201d said ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T22:03:08+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD\",\"datePublished\":\"2023-03-27T22:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/\",\"name\":\"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-27T22:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/","og_locale":"en_US","og_type":"article","og_title":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics, Inc. has expanded its Scientific Advisory Board with the appointment of Michael Houston, PhD, former Chief Scientific Officer of TriLink the leading mRNA Contract Research Organization. \u201cIt is a great privilege for Cytonus to be joined by Dr. Houston, who has contributed important advances in the field of mRNA therapeutics,\u201d said ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-27T22:03:08+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD","datePublished":"2023-03-27T22:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/"},"wordCount":640,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/","url":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/","name":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-27T22:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cytonus-expands-its-scientific-advisory-board-with-mrna-expert-michael-houston-phd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55229"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55229\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}